The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Primary IOL implantation in pediatric open globe injuries with active inflammation showed inferior visual outcomes compared ...

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients ...

Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.

Johnson & Johnson (JNJ) wins FDA approval for Tecnis PureSee intraocular lens ((IOL)), giving eye surgeons a new lens option for use in cataract surgery. Read more here.

The new approvals are the latest in Johnson & Johnson’s IOLs; the Company claims the new TECNIS Eyhance IOL can slightly extend the depth of focus and deliver better image contrast. The Food and Drug ...

Celebrating 75 years of intraocular lens advancements that have improved care for millions of cataract patients. On November 29, 1949, Sir Harold Ridley performed a surgical procedure to replace a ...

Cataract surgery remains one of the most frequently performed and successful surgical procedures worldwide, involving the removal of a clouded natural lens and its replacement with an intraocular lens ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...